{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:56:56Z","timestamp":1780372616150,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40264-020-00904-9","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T13:02:43Z","timestamp":1580475763000},"page":"379-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01976364","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gerd R.","family":"Burmester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifeng","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valderilio F.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F. C.","family":"Rigby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Kanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Palmetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs","family":"Hendrikx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"issue":"5","key":"904_CR1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felquer ML, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060\u201371.","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"904_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"904_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section\u00a02. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851\u201364.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"904_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","volume":"74","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423\u201341.","journal-title":"Drugs."},{"key":"904_CR5","first-page":"35","volume":"18","author":"P Nadarajan","year":"2016","unstructured":"Nadarajan P, Fabre A, Kelly E. Sulfasalazine: a rare cause of acute eosinophilic pneumonia. Respir Med Case Rep. 2016;18:35\u20136.","journal-title":"Respir Med Case Rep."},{"issue":"5 Suppl 61","key":"904_CR6","first-page":"S132","volume":"28","author":"A Ceponis","year":"2010","unstructured":"Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S132\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"904_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.dld.2003.06.002","volume":"36","author":"C Sevilla-Mantilla","year":"2004","unstructured":"Sevilla-Mantilla C, Ortega L, Ag\u00fandez JA, Fern\u00e1ndez-Guti\u00e9rrez B, Ladero JM, D\u00edaz-Rubio M. Leflunomide-induced acute hepatitis. Dig Liver Dis. 2004;36(1):82\u20134.","journal-title":"Dig Liver Dis."},{"issue":"11","key":"904_CR8","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3899\/jrheum.100041","volume":"37","author":"MS Krathen","year":"2010","unstructured":"Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol. 2010;37(11):2205\u201315.","journal-title":"J Rheumatol"},{"issue":"sup1","key":"904_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","volume":"15","author":"S Minozzi","year":"2016","unstructured":"Minozzi S, Bonovas S, Lytras T, Pecoraro V, Gonz\u00e1lez-Lorenzo M, Bastiampillai AJ, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(sup1):11\u201334.","journal-title":"Expert Opin Drug Saf."},{"issue":"16","key":"904_CR10","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537\u201350.","journal-title":"N Engl J Med"},{"issue":"16","key":"904_CR11","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525\u201336.","journal-title":"N Engl J Med"},{"key":"904_CR12","first-page":"682","volume":"76","author":"P Nash","year":"2017","unstructured":"Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, up to 24\u00a0months in patients with active psoriatic arthritis: interim data from OPAL Balance, an open-label, long-term extension study. Ann Rheum Dis. 2017;76:682 (FRI0509).","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"904_CR13","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","volume":"74","author":"KL Winthrop","year":"2015","unstructured":"Winthrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis. 2015;74(12):2107\u201316.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"904_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0010-4825(92)90023-G","volume":"22","author":"L Daly","year":"1992","unstructured":"Daly L. Simple SAS macros for the calculation of exact binomial and Poisson confidence limits. Comput Biol Med. 1992;22(5):351\u201361.","journal-title":"Comput Biol Med"},{"issue":"11","key":"904_CR15","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","volume":"73","author":"JW Baddley","year":"2014","unstructured":"Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis. 2014;73(11):1942\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"904_CR16","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/acr.21564","volume":"64","author":"A Bharat","year":"2012","unstructured":"Bharat A, Xie F, Baddley JW, Beukelman T, Chen L, Calabrese L, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res (Hoboken). 2012;64(4):612\u20135.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"11","key":"904_CR17","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/pds.2215","volume":"20","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Chen SY, Werther W, John A, Johnson DA. Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients. Pharmacoepidemiol Drug Saf. 2011;20(11):1150\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"904_CR18","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1002\/acr.21764","volume":"64","author":"JR Curtis","year":"2012","unstructured":"Curtis JR, Lanas A, John A, Johnson DA, Schulman KL. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(12):1819\u201328.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"904_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","volume":"17","author":"JR Curtis","year":"2015","unstructured":"Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study. Arthritis Res Ther. 2015;17:319.","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"904_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/art.37740","volume":"65","author":"K Haynes","year":"2013","unstructured":"Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, Graham DJ, et al. Tumor necrosis factor \u03b1 inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum. 2013;65(1):48\u201358.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"904_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","volume":"148","author":"Y Kiyota","year":"2004","unstructured":"Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148(1):99\u2013104.","journal-title":"Am Heart J"},{"issue":"4","key":"904_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCOUTCOMES.113.000743","volume":"7","author":"H Kumamaru","year":"2014","unstructured":"Kumamaru H, Judd SE, Curtis JR, Ramachandran R, Hardy NC, Rhodes JD, et al. Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims. Circ Cardiovasc Qual Outcomes. 2014;7(4):611\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"3","key":"904_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jclinepi.2008.06.006","volume":"62","author":"NM Patkar","year":"2009","unstructured":"Patkar NM, Curtis JR, Teng GG, Allison JJ, Saag M, Martin C, et al. Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol. 2009;62(3):321\u20137.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"904_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","volume":"152","author":"FI Scott","year":"2016","unstructured":"Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol. 2016;152(2):164\u201372.","journal-title":"JAMA Dermatol."},{"issue":"5","key":"904_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10552-007-0131-1","volume":"18","author":"S Setoguchi","year":"2007","unstructured":"Setoguchi S, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S. Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control. 2007;18(5):561\u20139.","journal-title":"Cancer Causes Control"},{"issue":"3","key":"904_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/pds.2049","volume":"20","author":"KL Winthrop","year":"2011","unstructured":"Winthrop KL, Baxter R, Liu L, McFarland B, Austin D, Varley C, et al. The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. Pharmacoepidemiol Drug Saf. 2011;20(3):229\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"904_CR27","doi-asserted-by":"publisher","first-page":"A107","DOI":"10.1136\/annrheumdis-2011-200690","volume":"72","author":"KL Winthrop","year":"2013","unstructured":"Winthrop KL, Neal J, Hrycaj P, Soma K, Wilkinson B, Hodge J, et al. Evaluation of influenza and pneumococcal vaccine responses in rheumatoid arthritis patients using tofacitinib. Ann Rheum Dis. 2013;72:A107\u20138 (OP0163).","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"904_CR28","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1002\/art.39761","volume":"68","author":"F Xie","year":"2016","unstructured":"Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68(11):2612\u20137.","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"904_CR29","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/aje\/kwr206","volume":"174","author":"BP Yawn","year":"2011","unstructured":"Yawn BP, Wollan P, St Sauver J. Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? Am J Epidemiol. 2011;174(9):1054\u201361.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"904_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/acr.22470","volume":"67","author":"H Yun","year":"2015","unstructured":"Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken). 2015;67(5):731\u20136.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"7","key":"904_CR31","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u00a0years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253\u201362.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"904_CR32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","volume":"74","author":"KA Papp","year":"2016","unstructured":"Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"904_CR33","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Pan\u00e9s J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616\u201324.","journal-title":"N Engl J Med"},{"issue":"6","key":"904_CR34","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","volume":"76","author":"S Ramiro","year":"2017","unstructured":"Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101\u201336.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"904_CR35","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/acr.22815","volume":"68","author":"RJ Desai","year":"2016","unstructured":"Desai RJ, Thaler KJ, Mahlknecht P, Gartlehner G, McDonagh MS, Mesgarpour B, et al. Comparative risk of harm associated with the use of targeted immunomodulators: a systematic review. Arthritis Care Res (Hoboken). 2016;68(8):1078\u201388.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"Suppl 10","key":"904_CR36","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(Suppl 10):2675\u201384.","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"904_CR37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaad.2017.03.023","volume":"77","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Lebwohl M, Cohen AD, Weinberg JM, Tyring SK, Rottinghaus ST, et al. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017;77(2):302\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"904_CR38","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69(10):1960\u20138.","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"904_CR39","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1133\u20138.","journal-title":"Ann Rheum Dis"},{"key":"904_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-0-387-77574-6_8","volume":"624","author":"U Leiter","year":"2008","unstructured":"Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer\u2013the role of sunlight. Adv Exp Med Biol. 2008;624:89\u2013103.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"904_CR41","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis. 2013;72(4):517\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"904_CR42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3899\/jrheum.120906","volume":"40","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8\u00a0years of treatment from the abatacept clinical trial program. J Rheumatol. 2013;40(6):787\u201397.","journal-title":"J Rheumatol"},{"issue":"1","key":"904_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2013-203660","volume":"74","author":"VP Bykerk","year":"2015","unstructured":"Bykerk VP, Cush J, Winthrop K, Calabrese L, Lortholary O, de Longueville M, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2015;74(1):96\u2013103.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"904_CR44","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/ard.2008.094839","volume":"68","author":"DD Gladman","year":"2009","unstructured":"Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68(7):1131\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"904_CR45","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","volume":"74","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"904_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/acr.22926","volume":"69","author":"A Polachek","year":"2017","unstructured":"Polachek A, Touma Z, Anderson M, Eder L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2017;69(1):67\u201374.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"3","key":"904_CR47","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","volume":"46","author":"C Charles-Schoeman","year":"2016","unstructured":"Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, Boy M, Zuckerman A, Soma K, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum. 2016;46(3):261\u201371.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"904_CR48","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","volume":"75","author":"JJ Wu","year":"2016","unstructured":"Wu JJ, Strober BE, Hansen PR, Ahlehoff O, Egeberg A, Qureshi A, et al. Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. J Am Acad Dermatol. 2016;75(5):897\u2013905.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"904_CR49","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","volume":"71","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019;71(7):1042\u201355.","journal-title":"Arthritis Rheumatol."},{"issue":"10139","key":"904_CR50","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513\u201324.","journal-title":"Lancet"},{"key":"904_CR51","unstructured":"US Food and Drug Administration. XELJANZ\u00ae (tofacitinib): Highlights of prescribing information. 2019. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959. Accessed 29 Oct 2019."},{"key":"904_CR52","unstructured":"European Medicines Agency. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_en.pdf. Accessed 15 Nov 2019."},{"issue":"5\u20136","key":"904_CR53","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/BF03256784","volume":"23","author":"D Matsui","year":"2009","unstructured":"Matsui D. Strategies to measure and improve patient adherence in clinical trials. Pharm Med. 2009;23(5\u20136):289\u201397.","journal-title":"Pharm Med."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00904-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00904-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00904-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T23:34:20Z","timestamp":1695684860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00904-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00904-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"assertion":[{"value":"31 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Carole Evans, PhD, and Richard Knight, PhD, CMC Connect, McCann Health Medical Communications Ltd, and was funded by Pfizer Inc, New York, NY, USA, in accordance with good publication practice (GPP3) guidelines (<i>Ann Intern Med<\/i> 2015;163:461\u20134).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gerd R. Burmester has received consulting fees from AbbVie, Gilead, Lilly, and Pfizer Inc and lecture fees from AbbVie, Lilly, and Pfizer Inc. Jeffrey R. Curtis has received research grants and consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Eli Lilly, Janssen, Myriad, Pfizer Inc, Regeneron, Roche, and UCB. Huifeng Yun has received grant\/research support from Pfizer Inc. Oliver FitzGerald has received research grants and honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer Inc, and UCB. Kevin L. Winthrop has received consulting fees from AbbVie, Galapagos, Gilead, GSK, Lilly, Pfizer Inc, Roche, and UCB. Valderilio F. Azevedo has received grant\/research support and consulting fees from AbbVie, Lilly, Novartis, and Pfizer Inc and lecture fees from AbbVie, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Novartis, and Pfizer Inc. William\u00a0F.C.\u00a0Rigby has received consulting fees for work unrelated to this manuscript. Keith S. Kanik, Cunshan Wang, Pinaki\u00a0Biswas, Thomas Jones, Thijs Hendrikx, and Ricardo\u00a0Rojo are shareholders and employees of Pfizer Inc. Sujatha Menon is an employee of Pfizer Inc. Niki Palmetto was an employee of Pfizer Inc at the time of the analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board or independent ethics committee at each investigational site and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Patient data from the US Truven MarketScan database were de-identified and complied with the patient confidentiality requirements of the Health Insurance Portability and Accountability Act. Therefore, institutional review board approval was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving Human Participants and\/or Animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}